Evidence map›Paper›PMID 29401301›Full record

ReviewNucleic acids research2018

Single molecule real-time (SMRT) sequencing comes of age: applications and utilities for medical diagnostics.

Simon Ardui, Adam Ameur, Joris R Vermeesch, Matthew S Hestand

Abstract readReview
In one paragraph

Review in Nucleic acids research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 327 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
327citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

327 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Complete genome sequence ofMicrobiology resource announcements · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Glycan Sequencing, A Brief Primer.Glycoscience & therapy · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Detection of CRISPR-Cas-induced mutations inbioRxiv : the preprint server for biology · 2025
    Article
  17. Review
  18. Article
  19. Review
  20. Review

267 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Simon ArduiDepartment of Human Genetics, KU Leuven, Leuven 3000, Belgium.
Adam AmeurDepartment of Immunology, Genetics and Pathology, Uppsala University, Science for Life Laboratory, Uppsala 75108, Sweden.
Joris R VermeeschDepartment of Human Genetics, KU Leuven, Leuven 3000, Belgium.
Matthew S HestandDepartment of Human Genetics, KU Leuven, Leuven 3000, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Short read massive parallel sequencing has emerged as a standard diagnostic tool in the medical setting. However, short read technologies have inherent limitations such as GC bias, difficulties mapping to repetitive elements, trouble discriminating paralogous sequences, and difficulties in phasing alleles. Long read single molecule sequencers resolve these obstacles. Moreover, they offer higher consensus accuracies and can detect epigenetic modifications from native DNA. The first commercially available long read single molecule platform was the RS system based on PacBio's single molecule real-time (SMRT) sequencing technology, which has since evolved into their RSII and Sequel systems. Here we capsulize how SMRT sequencing is revolutionizing constitutional, reproductive, cancer, microbial and viral genetic testing.

Indexed as

Bacterial InfectionsDNAHigh-Throughput Nucleotide SequencingHumansModels, MolecularMolecular Diagnostic TechniquesNeoplasmsNucleic Acid ConformationSensitivity and SpecificityVirus DiseasesDNA

Identifiers

PMID29401301
PMCPMC5861413

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.